Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Comment by mercedesmanon Nov 25, 2021 5:53pm
145 Views
Post# 34166745

RE:RE:SQI's EXACT Covid-19 Antibody in need all across the globe.

RE:RE:SQI's EXACT Covid-19 Antibody in need all across the globe. Morris described it as a Catch-22, which believe is accurate.

I believe the impasse will be broken in three ways.

1) Gov't needs the Antibody data like they do for other viruses...even much more so in order to help save future lives, and manage future booster strategies. One size fits all strategies and political expediencey strategies (e.g. take your booster every 6 months) will soon wear thin with the public....especially in this era of mistrust.  It will also be too costly for Governments (e.g. perhaps certain people only need a booster every two years?,, or perhaps some people will elect to assume more risk in order to take fewer jabs) 
2)  regulating interpretation by medical professionals (at least at the beginning) will help
3) Political pressure by the 20% of the population that wants to better manage thier family's health and the number and frequency of future jabs.

I think we have to let the early adopters (concerned individuals with the means) help to build the database and create the standards for the rest to follow. An Antibody test presents no risk, and only arms the payer (jabee) with more and important information (as well as eventually the regulators)

With 400 million people in the US and Canada, even the early adopters represent a massive market.  20 % = 80 million people.  And if Covid becomes the Endemic that many think it will become, then multiple tests per individual per year could quickly becomes the norm.  

The growth comes from the other 80% and everyone and every country outside of NA.

MM


25Stone7859 wrote: I note your post's German data was first published in April, 2020; is it still relevant?  CEO Morris in the  recentToronto Star article stated that there were Government barriers in the USA and Canada about utilizing Antibidy test results. This is puzzling news to me and I think other shareholders. Who and what are going to change the mind-set of the FDA and Health Canada? I believe SQI has to come forward now and clarify its position vis-a-vis these Regulatory bodies and explain in greater detail why this COVID-19 Strategy is going to be successful. 


<< Previous
Bullboard Posts
Next >>